Change in pharmacodynamic variables following once‐weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J‐mono substudy)

AIM: To evaluate the pharmacodynamic effects of tirzepatide, a novel dual glucagon‐like peptide‐1 receptor and glucose‐dependent insulinotropic polypeptide receptor agonist, compared with dulaglutide in patients with type 2 diabetes. MATERIALS AND METHODS: SURPASS J‐mono was a 52‐week, multicentre,...

Descripción completa

Detalles Bibliográficos
Autores principales: Yabe, Daisuke, Kawamori, Dan, Seino, Yusuke, Oura, Tomonori, Takeuchi, Masakazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092154/
https://www.ncbi.nlm.nih.gov/pubmed/36184780
http://dx.doi.org/10.1111/dom.14882

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092154/
https://www.ncbi.nlm.nih.gov/pubmed/36184780
http://dx.doi.org/10.1111/dom.14882

Ejemplares similares